Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4 , and an inhibitor of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL pro inhibitor with an IC 50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Glioma | Products > Disease Areas > HIV Infection | Products > Disease Areas > Pain | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > P-glycoprotein | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > HIV | Products > Signaling Pathways > HIV Protease | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Cytochrome P450
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye